Business Case Studies, Mergers, Acquisitions and Takeovers Case Study, Novartis' Acquisition of Chiron,Access to vaccine market

print page
Tell A Friend

Case Categories

Mergers, Acquisitions and Takeovers Case Study

Case Title:

Novartis' Acquisition of Chiron: Access to vaccine market

Publication Year : 2006

Authors: Supratim Majumdar, Kumar Satyaki Ray

Industry: Health Care


Case Code: MAA0086K

Teaching Note: Not Available

Structured Assignment: Not Available

Buy This Case Study

Novartis AG (Novartis) was a leading global pharmaceutical (pharma) company. In the recent times, the company had not achieved much success in developing new drugs. Moreover, many of its drugs had either lost patent protection or were going to face the same in the next few years. The company was facing tough competition from generic drug makers, which had adversely affected its future growth prospect. In order to retain its leading position in the pharma industry, the company diversified into other segments, thereby expanding its product portfolio and geographic reach. In 2005, Novartis acquired the Chiron Corporation (Chiron), a leading pharma company having strong presence in vaccines, blood testing and biopharmaceuticals. This case deals with Novartis’ acquisition of Chiron, which would help the former to enter into vaccine and blood-testing businesses for the first time and strengthen its biopharmaceuticals business segment. The case has provided background notes on the two companies and a detailed description of the pre-merger scenario of Novartis. It also discusses the acquisition deal in details. The case puts forth the rationale behind the acquisition and the expected benefits for Novartis. It finally discusses the possible challenges which Novartis can face in the near future. The case also provides a detailed note on the structure and future trends of the global vaccine market.

Pedagogical Objectives:

  • To understand global vaccine market
  • To understand the growth strategy through acquisitions
  • To analyse the rational behind any M&A deal
  • To analyse framework for successful merger, blueprint for integrating acquisitions
  • To discuss strategic reasons for M&A value creation.

Keywords : Mergers,Acquisitions,Alliances Case Study;Novartis AG; Chiron Corporation; Pharmaceutical industry; Biopharmaceuticals; Vaccines; Blood testing equipment; Avian flu / bird flu; Influenza vaccine; HIV/AIDS; Merger synergies; Global vaccine market; NAT (nucleic acid testing) technology

Contents : 
Global Vaccine Market: A Brief Overview
Novartis: Pre-Merger Scenario
Merger Rationale
Top 20 Global Pharma Companies
Novartis – Different Division
Vaccines Reduced The Incidence Of Infections

Recently Bought Case Studies

    Recently Bought Case Studies

    Executive Interviews

  • Dr James O` TooleDr James O` Toole

    Dr James O` Toole, Daniels Distinguished Professor of Business Ethics at the University of Denver’s Daniels College of Business
    Speaks on The Making of a CEO
  • Paul BrackenPaul Bracken

    Prof. Paul Bracken, leading expert in global competition and the strategic application of technology in business and defense.
    Speaks on Midlife Crisis
  • Bill FischerBill Fischer

    Bill Fischer, Professor of Technology, IMD
    Speaks on Building High Performance Teams
  • View All Executive Interviews»

Contact us: IBS Case Development Centre (IBSCDC), IFHE Campus, Donthanapally, Sankarapally Road, Hyderabad-501203, Telangana, INDIA.
Mob: +91- 9640901313,

©2020 - 25 IBS Case Development Centre. All rights reserved. | Careers | Privacy Policy | Terms of Use | Disclosure | Site Map xml sitemap